| Placebo# | CIC 320 µg·day−1 | CIC 640 µg·day−1 | FP 500 µg·day−1 | FP 1000 µg·day−1 |
Serum cortisol mesor nmol·L−1 | | | | | |
Subjects n | 27 | 27 | 27 | 27 | 29 |
Mean±sd | 381.2±98.5 | 352.8±110.4 | 341.6±95.9 | 332.9±94.2 | 304.4±150.6 |
LS mean±sem | 369.2±22.6 | 341.0±22.7 | 331.8±22.7 | 323.0±22.6 | 293.0±22.3 |
Difference versus placebo | | | | | |
LS mean±sem | | -28.2±18.8 | -37.3±18.8 | -46.2±19.0 | -76.1±18.6 |
95% CI | | -65.5–9.2 | -74.7–0.0 | -83.8– -8.5 | -112.9– -39.3 |
p-value | | 0.0251 | 0.0687 | 0.0084 | <0.0001 |
Difference versus FP 1000 µg·day−1 | | | | | |
LS mean±sem | 76.1±18.6 | 48.0±18.6 | 38.8±18.6 | 30.0±18.7 | |
95% CI | 39.3–112.9 | 11.1–84.8 | 1.9–75.7 | -7.2–67.1 | |
p-value | 0.0001 | 0.0057 | 0.0197 | 0.0563 | |
Change in serum cortisol to placebo % | | | | | |
Subjects n | | 26 | 26 | 25 | 27 |
Mean±sd | | -6.1±26.1 | -7.9±18.5 | -10.3±20.9 | -19.8±28.0 |
24-h urine cortisol adjusted for creatine nmol·mmol−1 | | | | | |
Subjects n | 25 | 26 | 27 | 27 | 28 |
Mean±sd | 25.74±17.24 | 22.95±10.17 | 23.72±10.75 | 20.49±7.49 | 20.74±10.93 |
LS mean±sem after treatment | 25.04±2.44 | 22.12±2.43 | 23.32±2.39 | 20.06±2.39 | 19.80±2.37 |
Difference versus placebo LS mean±sem | | -2.92±2.38 | -1.72±2.35 | -4.98±2.36 | -5.24±2.32 |
95% CI | | -7.64–1.80 | -6.38–2.94 | -9.66– -0.30 | -9.84– -0.64 |
p-value | | 0.1111 | 0.2326 | 0.0186 | 0.0130 |